Who are Erigeron breviscapus injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Standard treatment+Xiyanping injection, Xueshuantong lyophilized powder, HUACHANSU PIAN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/erigeron-breviscapus-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Erigeron breviscapus injection — Competitive Intelligence Brief

Erigeron breviscapus injection (Erigeron breviscapus injection) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine extract; antiplatelet/microcirculation enhancer. Area: Cardiovascular; Cerebrovascular/Neurology.

marketed Traditional Chinese medicine extract; antiplatelet/microcirculation enhancer Cardiovascular; Cerebrovascular/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Erigeron breviscapus injection (Erigeron breviscapus injection) — Guangzhou University of Traditional Chinese Medicine. Erigeron breviscapus injection reduces blood viscosity and improves microcirculation by inhibiting platelet aggregation and promoting vasodilation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Erigeron breviscapus injection TARGET	Erigeron breviscapus injection	Guangzhou University of Traditional Chinese Medicine	marketed	Traditional Chinese medicine extract; antiplatelet/microcirculation enhancer
Standard treatment+Xiyanping injection	Standard treatment+Xiyanping injection	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	marketed	Traditional Chinese medicine extract
Xueshuantong lyophilized powder	Xueshuantong lyophilized powder	Dongzhimen Hospital, Beijing	marketed	Traditional Chinese medicine extract
HUACHANSU PIAN	HUACHANSU PIAN	Beijing Shenogen Biomedical Co., Ltd	phase 3	Traditional Chinese medicine extract; natural product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine extract; antiplatelet/microcirculation enhancer class)

Guangzhou University of Traditional Chinese Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erigeron breviscapus injection — Competitive Intelligence Brief. https://druglandscape.com/ci/erigeron-breviscapus-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab